Tobam grew its position in Bristol-Myers Squibb Company (NYSE:BMY) by 38.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,096,089 shares of the biopharmaceutical company’s stock after buying an additional 302,375 shares during the quarter. Bristol-Myers Squibb accounts for 2.3% of Tobam’s holdings, making the stock its 10th largest holding. Tobam owned approximately 0.07% of Bristol-Myers Squibb worth $61,074,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of BMY. Pacer Advisors Inc. grew its stake in Bristol-Myers Squibb by 6.3% during the 2nd quarter. Pacer Advisors Inc. now owns 37,947 shares of the biopharmaceutical company’s stock worth $2,114,000 after purchasing an additional 2,250 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp boosted its position in shares of Bristol-Myers Squibb by 1.4% during the 2nd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 3,434,153 shares of the biopharmaceutical company’s stock worth $191,351,000 after acquiring an additional 46,301 shares in the last quarter. BDO Wealth Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb in the 2nd quarter valued at about $123,000. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its holdings in shares of Bristol-Myers Squibb by 16.0% in the 2nd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 388,247 shares of the biopharmaceutical company’s stock valued at $21,633,000 after purchasing an additional 53,468 shares during the last quarter. Finally, Airain ltd purchased a new stake in shares of Bristol-Myers Squibb in the 2nd quarter valued at about $527,000. 69.14% of the stock is owned by institutional investors and hedge funds.

In related news, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at $2,777,820. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.23% of the stock is currently owned by company insiders.

Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at $60.86 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. The firm has a market capitalization of $99,609.56, a PE ratio of 20.56, a PEG ratio of 2.40 and a beta of 1.18. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). The firm had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter last year, the business posted $0.77 earnings per share. sell-side analysts predict that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Investors of record on Friday, October 6th were paid a $0.39 dividend. The ex-dividend date of this dividend was Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.56%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 61.42%.

Several research firms have commented on BMY. Hilliard Lyons downgraded Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price objective for the company. in a research note on Tuesday, September 12th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $65.00 price objective (up from $62.00) on shares of Bristol-Myers Squibb in a research note on Thursday, September 7th. SunTrust Banks, Inc. raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. Barclays PLC boosted their target price on Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Friday, October 13th. Finally, Jefferies Group LLC boosted their target price on Bristol-Myers Squibb from $66.00 to $72.00 and gave the stock a “buy” rating in a research report on Monday, September 11th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company’s stock. Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus price target of $64.93.

ILLEGAL ACTIVITY WARNING: This news story was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.dailypolitical.com/2017/11/12/tobam-has-61-07-million-holdings-in-bristol-myers-squibb-company-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.